ANAB vs GBX Comparison

AnaptysBio Inc is a clinical-stage biotechnology company. The company is focused on developing antibody product candidates for unmet medical needs in inflammation and immuno-oncology. The company is developing immune cell modulating antibodies, including two wholly owned checkpoint agonists in clinical-stage development, for autoimmune and inflammatory diseases; rosnilimab, PD-1 agonist in a Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis (RA) and a Phase 2 trial for the treatment of moderate-to-severe ulcerative colitis (UC); and ANB032, BTLA agonist, in a Phase 2b trial for the treatment of moderate-to-severe atopic dermatitis (AD).

Greenbrier Companies Inc supplies equipment and services to international freight transportation markets, designing and marketing freight railcars in North America, Europe, and Brazil through subsidiaries and joint ventures. It provides railcar wheel services, parts, maintenance, and conversion services in North America. The company owns a lease fleet sourced mainly from its manufacturing operations and offers railcar management, regulatory compliance, and leasing services to railroads and owners. It operates two segments: Manufacturing and Leasing & Fleet Management, with the majority of revenue from Manufacturing. The company operates in the U.S. and internationally, with the majority of revenue from the U.S. market.